https://www.selleckchem.com/pr....oducts/hsp990-nvp-hs
The loss of serum hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CH is considered an ideal clinical outcome but rarely achieved with current standard of care. We evaluated the effectiveness in inducing HBsAg seroclearance in a real-world clinical cohort of Chinese patients with CHB treated with a combination of pegylated interferon (Peg-IFN) with tenofovir disoproxil fumarate (TDF) or monotherapy with each agent. A total of 330 patients with CHB were assigned to receive Peg-IFN plus TDF for 48 week
Like
Comment
Share
